A Prospective Study of CD38/45 Flow Cytometry and Immunofluorescence Microscopy to Detect Blood Plasma Cells in Patients with Plasma Cell Proliferative Disorders

Malignant plasma cells can be detected in the blood of patients with multiple myeloma (MM) using flow cytometry (FC), immunofluorescence microscopy (IM), or a variety of molecular techniques. Increased numbers of light chain-restricted blood plasma cells as detected by IM is associated with a diagnosis of overt MM and a decreased overall survival. The IM technique is time consuming; therefore, a prospective study was designed to test whether CD38 CD45 FC could simplify the procedure. Blood samples from 769 patients with plasma cell proliferative disorders were studied prospectively by FC and IM over a one-year period. The FC technique was performed on 1 ml of whole blood after ammonium chloride red blood cell lysis and utilized anti-CD38PE and anti-CD45PerCP. The number of CD38+ 45- events were enumerated and compared to the number of light chain-restricted plasma cells detected by the standard IM technique. In 46% (353/769) of cases ≥1 CD38+ CD45- events were detected by FC whereas IM was positive for light chain restricted plasma cells in 33%; there was concordance between FC and IM in 73% of cases. In 20% of cases FC was positive and IM was negative; however, in 7% of cases FC was negative yet light chain-restricted plasma cells were detected by IM. FC was positive in 88% (134/153) of cases where the IM technique showed a high number of circulating plasma cells. This study demonstrates that two-color CD38/45 FC identifies most cases with a high IM result and reduces the workload in the clinical laboratory. The prognostic implications of a positive FC screen but a negative IM will require long-term patient follow-up.

[1]  H. Goldschmidt,et al.  Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.

[2]  S. Barrans,et al.  Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression , 1999, British journal of haematology.

[3]  H. Goldschmidt,et al.  Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. , 1998, Experimental hematology.

[4]  A. Morley,et al.  Longitudinal analysis of circulating myeloma cells detected by allele specific mRNA in situ hybridization , 1998, American journal of hematology.

[5]  F. Prósper,et al.  Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement , 1997, Leukemia.

[6]  G. Morgan,et al.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.

[7]  D. Huhn,et al.  Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen , 1997, British journal of haematology.

[8]  M. Litzow,et al.  Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation , 1997, Bone Marrow Transplantation.

[9]  W. O'Fallon,et al.  Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. , 1996, Blood.

[10]  R. Kyle,et al.  Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. , 1996, Blood.

[11]  G. Ahmann,et al.  Detection of myeloma cells in the peripheral blood by flow cytometry. , 1996, Cytometry.

[12]  A. Kuramoto,et al.  Identification of early plasma cells in peripheral blood and their clinical significance , 1996, British journal of haematology.

[13]  W. O'Fallon,et al.  Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma , 1994, British journal of haematology.

[14]  M. Dhodapkar,et al.  Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma , 1993, Cancer.

[15]  J. Katzmann,et al.  Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Palumbo,et al.  Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Pilarski,et al.  A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. , 1998, Blood.

[18]  R. Kyle,et al.  Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest? , 1995, Leukemia & lymphoma.